Abstract: A vehicle braking system includes a processing device, a linear actuator, a master cylinder, and a braking caliper. The processing device is configured to receive a heartbeat from an operating vehicle. The linear actuator is communicatively coupled to the processing device. The master cylinder is coupled to the linear actuator. Upon not receiving the heartbeat within a threshold period of time, the processing device is configured to transmit a signal to the linear actuator to cause a force to be transmitted to the master cylinder, actuating the braking caliper, and causing the operating vehicle to stop.

Abstract: The present invention relates to new immunocytokines which are useful for the treatment of cancer. These fusion proteins comprise (i) an antibody or antigen-binding fragment thereof fused to (ii) a cleavable peptide linker, and (iii) cytokine, or functional fragments thereof. Methods of treatment using these immunocytokines are also disclosed.

Abstract: The present invention relates to new immunocytokines which are useful for the treatment of cancer. These fusion proteins comprise (i) an antibody or antigen-binding fragment thereof fused to (ii) a cleavable peptide linker, and (iii) cytokine, or functional fragments thereof. Methods of treatment using these immunocytokines are also disclosed.

Abstract: The present invention relates to new immunocytokines which are useful for the treatment of cancer. These fusion proteins comprise (i) an antibody or antigen-binding fragment thereof fused to (ii) a cleavable peptide linker, and (iii) cytokine, or functional fragments thereof. Methods of treatment using these immunocytokines are also disclosed.

Abstract: The present invention relates to new immunocytokines which are useful for the treatment of cancer. These fusion proteins comprise (i) an antibody or antigen-binding fragment thereof fused to (ii) a cleavable peptide linker, and (iii) cytokine, or functional fragments thereof. Methods of treatment using these immunocytokines are also disclosed.

Abstract: The present disclosure relates to the treatment of cancers and, more particularly, to the treatment of ADAM17 substrate dependant cancers which are refractory. The pharmaceutical composition contains an ADAM17 antibody (it recognizes an epitope within the membrane proximal domain of ADAM17 localized between the residues 564 and 642) characterized by the sequences of its variable chains.

Abstract: The present disclosure relates to a novel humanized antibody capable of binding to ADAM17 and also the amino and nucleic acid sequences coding for said antibody. From one aspect, the disclosure relates to a novel humanized antibody, or antigen-binding fragments, capable of binding to ADAM17 with anti-tumour activities. The disclosure also comprises the use of said humanized antibody as a drug for the treatment of cancer. Finally, the invention comprises compositions comprising said humanized antibody, alone or in combination or conjugation with other anticancer compounds, and the use of same for the treatment of cancer.

Abstract: The invention relates to a method for generating a DNA sequence coding for the heavy chain or the light chain of at least one antibody from RNA from a cell capable of producing an antibody. More particularly, the invention relates to the generation of a monoclonal antibody library. The invention also relates to the use of an antibody library for screening monoclonal antibodies, preferably human antibodies for treating cancer.

Abstract: The present invention relates to a novel antibody capable of binding to ADAM17 and also the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to a novel antibody, or antigen-binding fragments, capable of binding to ADAM17 with anti-tumour activities. The invention also comprises the use of said antibody as a drug for the treatment of cancer. Finally, the invention comprises compositions comprising said antibody, alone or in combination or conjugation with other anti-cancer compounds, and the use of same for the treatment of cancer.

Abstract: Systems are described herein for providing card reader configuration and access control, including a card reader, a remote computing device, and a communications network coupled to the card reader and the remote computing device. The card reader is configured to connect to the remote computing device via the communications network, transmit a request to the remote computing device via the communications network, receive data from the remote computing device via the communications network, and configure operational settings based on the received data. The remote computing device is configured to receive the request from the card reader via the communications network, generate data responsive to the request, and transmit the data to the card reader via the communications network.

Abstract: Methods and systems are described herein for providing configuration and access control of a card reader using a secure channel between the card reader and a remote computing device. The card reader transmits a request for service to the remote computing device via a cloud-based communications network. The remote computing device receives the request for service via the cloud-based communications network and generates service instructions based on the received request for service. The remote computing device transmits the service instructions to the card reader via the cloud-based communications network. The card reader receives the service instructions from the remote computing device via the cloud-based communications network and configures operational settings based on the received service instructions.

Abstract: The invention relates to a minimized phage display vector comprising at least a cloning cassette, a phage display cassette and a bacterial cassette, said cloning cassette comprising a nucleic acid sequence encoding a polypeptide corresponding at least to the intra-domain loop of a constant domain of an antibody. It also relates to their uses for the production of libraries of phages, each phage expressing on its surface a binding protein to be screened for its capacity to bind a binding partner.

Abstract: The invention relates to a minimized phage display vector comprising at least a cloning cassette, a phage display cassette and a bacterial cassette, said cloning cassette comprising a nucleic acid sequence encoding a polypeptide corresponding at least to the intra-domain loop of a constant domain of an antibody. It also relates to their uses for the production of libraries of phages, each phage expressing on its surface a binding protein to be screened for its capacity to bind a binding partner.

Abstract: This invention relates to the pipeline corrosion prevention and third party strike pipeline damage. The detector comprises of dual axis Anisotropic Magnetoresistive (AMR) magnetic sensor, analog signal conditional circuitry, digital circuitry, and a display. A pipe current magnitude and direction is measured via magnetic field surrounding the pipe. Magnetic field is sensed by the Anisotropic Magnetoresistive (AMR) magnetic sensor. The sensor converts magnetic field values into an electrical potential difference. This potential difference is converted into digital data and displayed on either computer screen or an LCD display. The current reader will be installed on a pipe and take continuous magnetic field reads (amplitude and direction). Third party strike damage is detected by monitoring magnetic fields around a pipe and comparing them to a baseline magnetic field. Any mechanical damage on a pipe will distort baseline magnetic field value around the pipeline.

Abstract: A security screening facility for a location in which passengers travel from a check-in location within an in-secure area of a terminal to a secure part of the terminal for eventually boarding a transport vehicle. The facility includes a prefabricated building located alongside the terminal which houses body scanning apparatus.

Abstract: The invention relates to a method for generating a DNA sequence coding for the heavy chain or the light chain of at least one antibody from RNA from a cell capable of producing an antibody. More particularly, the invention relates to the generation of a monoclonal antibody library. The invention also relates to the use of an antibody library for screening monoclonal antibodies, preferably human antibodies for treating cancer.

Abstract: A system for screening items of baggage comprises attaching to each baggage item at a check-in location within a terminal an electronic tag which is periodically scanned as the item travels via baggage sortation system from the check-in location and a loading location. All baggage items are diverted from the sortation system to an explosive detection screening system housed within a prefabricated building alongside the terminal. Baggage items which are not cleared by the explosive detection screening system are retained within the building for further inspection and cleared baggage items are re-introduced into the sortation system for travel to the loading location.

Abstract: A system for screening items of baggage comprises attaching to each baggage item at a check-in location within a terminal an electronic tag which is periodically scanned as the item travels via baggage sortation system from the check-in location and a loading location. All baggage items are diverted from the sortation system to an explosive detection screening system housed within a prefabricated building alongside the terminal. Baggage items which are not cleared by the explosive detection screening system are retained within the building for further inspection and cleared baggage items are re-introduced into the sortation system for travel to the loading location.

Abstract: An RFID transponder detector is provided having a coupled oscillator system. Coupled first and second LC pairs of the system produce a detection signal each time a combination of pulses is applied to the LC pairs. Application of the pulses is repeated periodically to produce a sequence fo detection signals having two different first and second detection frequencies. Transmitting the sequence of detection signals results in corresponding first and second response signals having the first and second detection frequencies at the LC pairs. Values of a preselected detection parameter for the detection signals are compared to the values of the detection parameter for the response signals to determine if a transponder having a transponder resonant frequency corresponding to the first or second detection frequency is present in a proximal space of the transponder detector.